# About CJC-1295 Doctor — Editorial standards and scope

> Editorial standards, scope, and disclaimer for CJC-1295 Doctor — an independent research-summary site on the GHRH analog CJC-1295. Not a clinic, not a vendor, not affiliated with any product.

Editorial standards, scope, and the disclaimer that applies to every page.

## What this site is

CJC-1295 Doctor is an independent editorial site that summarizes the published research literature on CJC-1295. The pages here are written as a reading list — a way to locate the small set of peer-reviewed papers, regulatory documents, and registered clinical trials that anchor the compound's evidence base, and to summarize what each of those sources actually says.

The target reader is a physician, a research scientist, a science journalist, or a careful lay reader who wants the underlying citations and not the marketing layer that surrounds most peptide content online. The site is single-author in voice but compiled from peer-reviewed primary sources; every quantitative claim is anchored to a citation.

## What this site is not

This site is **not** a clinic, a pharmacy, a compounding service, a research-chemical vendor, or a treatment provider. It does **not** sell any product. It is **not** affiliated with ConjuChem (the original sponsor of CJC-1295's clinical development), with any compounding pharmacy, with any 'wellness clinic' that offers GHRH analog protocols, or with any peptide retailer.

It does **not** provide medical advice. The dosage page describes doses that appear in the published research; it does not recommend doses for any human research subject, patient, or athlete. CJC-1295 is not approved by the FDA or any other major regulator for any human indication, and it is prohibited at all times by the World Anti-Doping Agency for tested athletes.

## Editorial standards

Every quantitative claim on this site cites a real, peer-reviewed primary source, a registered clinical trial, or a regulatory document with a DOI or permanent URL. Inline citations are numbered [N] and resolve to entries on the [references](/references) page.

When a claim cannot be sourced to a peer-reviewed paper, it is either omitted or explicitly marked as deriving from a regulatory document or registry record. Where the literature is silent — for example, on long-term human safety beyond a few weeks — the silence is acknowledged rather than papered over with secondary-source assertions.

This site does not mention brand names of FDA-approved comparators, peptide vendor names, or compounding-pharmacy names. Where a comparator compound is discussed (sermorelin, tesamorelin, ipamorelin) it is named by its generic INN only.

## Disclaimer

Nothing on this site constitutes medical advice. Nothing here is an endorsement of CJC-1295 for any human use. This site is an independent editorial digest of the published CJC-1295 research record — not a clinic, not a pharmacy, not a vendor, not a treatment provider. Readers seeking medical guidance should consult a licensed clinician. Readers subject to WADA testing should treat CJC-1295 as a prohibited substance at all times.

---

An independent reading of publicly available CJC-1295 research — not a clinic, not a vendor, not a treatment recommendation.